ARX201 is a long-acting variant of human growth hormone that is being developed for the treatment of both adult and pediatric growth-hormone deficiency. In adults, the lack of growth hormone can result in metabolic syndromes, including increase in body fat, dyslipidemia and changes in cardiovascular outcome markers. In pediatrics, growth hormone is critical for achieving normal growth velocity and height at maturity. ARX201 has completed Phase 2b clinical studies in young adults. During the course of this 26 week study, weekly administration of ARX201 demonstrated normalization of IGF-1, a well-established pharmacodynamics marker of growth hormone activity. ARX201 is being prepared to enter adult Phase 3 and pediatric Phase 2 clinical studies in 2014.